Essential Thrombocythemia
📧 Sign up to get email alerts when something new happens for Essential Thrombocythemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms [Phase 1, Phase 2]
The Phase 1/2 study evaluating the combination of ruxolitinib and CPX-351 in advanced phase myeloproliferative neoplasms was terminated, wit…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) [Phase 3]
Phase 3 clinical trial evaluating Bomedemstat versus best available therapy in essential thrombocythemia patients with inadequate response o…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) [Phase 3]
Phase 3 clinical trial evaluating bomedemstat versus hydroxyurea for essential thrombocythemia is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) [Phase 2]
This Phase 2 trial from the University of Manitoba is evaluating antibiotic prophylaxis in patients with myelodysplastic syndrome and acute …
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms [Phase 1]
This clinical trial update announces a Phase 1 study of JNJ-88549968 for CALR-mutated myeloproliferative neoplasms and indicates the trial i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) [Phase 2]
A Phase 2 randomized trial evaluating ASTX727 with or without iadademstat in advanced myeloproliferative neoplasms, currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia [NA]
The ENERGIA study tests a personalized exercise program to reduce fatigue in patients with myeloproliferative neoplasms and chronic myeloid …
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) [Phase 3]
Phase 3 study of bomedemstat (MK-3543-017) sponsored by Merck is currently recruiting to evaluate safety and efficacy in essential thrombocy…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms [Phase 1]
An update on a Phase 1 safety and tolerability study of INCB057643 in myelofibrosis and other advanced myeloid neoplasms, with the trial cur…
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm [Phase 2]
This Phase 2 trial update reports completion of a study evaluating the combination of ruxolitinib phosphate and azacitidine in patients with…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms [Phase 2]
Phase 2 clinical trial evaluating curcumin to improve inflammation and symptoms in patients with clonal cytopenia of undetermined significan…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms [Phase 3]
Phase 3 clinical trial AVAJAK compares apixaban or rivaroxaban with aspirin for primary prevention of thromboembolic events in patients with…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms [Phase 2]
A Phase 2 clinical trial evaluating decitabine in combination with JAK inhibitors (ruxolitinib, fedratinib, or pacritinib) for accelerated o…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms [Phase 1, Phase 2]
This clinical trial aims to identify the optimal dose of N-acetylcysteine in patients with myeloproliferative neoplasms. It spans Phase 1/2 …
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
A clinical trial update focused on identifying factors associated with treatment response in patients with polycythemia vera, essential thro…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) [NA]
This clinical trial update notes a study investigating how CALR allele burden aids diagnosis and monitoring in CALR-mutated myeloproliferati…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia [Phase 1]
Phase 1 study of STP938 as monotherapy for high-risk Essential thrombocythemia is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
This entry describes the MPN PROGRESSion Registry, an observational study to track symptoms, treatments, and disease progression in people w…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis [Phase 2]
Phase 2 clinical trial evaluating elotuzumab for JAK2-mutated myelofibrosis; the study is active but not recruiting and includes myelofibros…
-
CLINICAL_TRIALS other · 2026-01-08Clinical Trial Update: Ruxolitinib in Thrombocythemia and Polycythemia Vera [Phase 2]
A Phase 2 trial of ruxolitinib for essential thrombocythemia and polycythemia vera is currently recruiting at Massachusetts General Hospital…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) [Phase 2]
Phase 2 clinical trial update for IMG-7289 in essential thrombocythemia and polycythemia vera; the study is currently active but not recruit…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial [Phase 2]
A Phase 2 clinical trial called TREATMORE evaluating MethoTRExATE in myeloproliferative neoplasms is currently recruiting for polycythemia v…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes [NA]
A clinical trial is ongoing to characterize monocytes in myeloproliferative neoplasms, with recruitment currently in progress.
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET [Phase 2]
Phase 2 trial assessing peginterferon alfa-2b for hydroxyurea-resistant or intolerant essential thrombocythemia is currently recruiting.
-
EMA approval · 2025-11-14EMA Authorised: Anagrelide Viatris (previously Anagrelide Mylan) (anagrelide hydrochloride) — Viatris Limited
The EMA has authorised Viatris' Anagrelide (anagrelide hydrochloride) for the treatment of essential thrombocythemia.